CVE-2022-15183.2.2 IMPROPER LIMITATION OF A PATHNAME TO A RESTRICTED DIRECTORY ('PATH TRAVERSAL') CWE-22
Updated under an hour ago ()
Does this affect you?
It affects Illumina NextSeq 550Dx and 7 other products. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 1.67%, higher than 77% of scored CVEs.
Do this next
Free account, 1 product
LRM contains a directory traversal vulnerability that can allow a malicious actor to upload outside the intended directory structure.
- CVSS
- 10.0 CRITICAL (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H
- Weakness (CWE)
- CWE-22
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 1.67% (percentile 77)
- Assigned by
- icscert
- NVD analysis
- Modified
- Record last updated
- Apr 16, 2025
- First seen by InfoSec Signals
- Oct 12, 2026
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.